[Abstract]

Tomaralimab is a fully-humanized IgG4 isotype antibody against Toll-like receptor 2 (TLR2). Neuramedy has identified that TLR2 plays critical roles in alpha-synuclein (aSyn) aggregate propagation and neuroinflammation which are well-recognized pathological features in Parkinson’s Disease (PD). The aim of this study is to validate beneficial effects of Tomaralimab in vitro and in vivo PD model systems.

Tomaralimab reduced aSyn aggregate-triggered TLR2 stimulation, microglial activation, and aSyn propagation in cultured cell systems. In PD mouse models, intravenously injected Tomaralimab reached the brain parenchyma and this was sufficient to ameliorate PD pathologies such as aSyn aggregation, gliosis, neuroinflammation, as well as behavioral defects.

These results strongly support the beneficial effects of Tomaralimab on PD pathologies in various model systems, providing a rationale for the therapeutic development of Tomaralimab for the cure of Parkinson’s disease.